Development of Lyophilised Eudragit^® Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration

Clozapine (CZP) is the only effective drug in schizophrenia resistant to typical antipsychotics. However, existing dosage forms (oral or orodispersible tablets, suspensions or intramuscular injection) show challenging limitations. After oral administration, CZP has low bioavailability due to a large...

Full description

Bibliographic Details

Published in:	Pharmaceutics
Main Authors:	Rosamaria Lombardo, Marika Ruponen, Jarkko Rautio, Carla Ghelardini, Lorenzo Di Cesare Mannelli, Laura Calosi, Daniele Bani, Riikka Lampinen, Katja M. Kanninen, Anne M. Koivisto, Elina Penttilä, Heikki Löppönen, Rosario Pignatello
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Subjects:	Eudragit RL100 Eudragit RS100 nanomedicine cryoprotectants mucoadhesion stability
Online Access:	https://www.mdpi.com/1999-4923/15/5/1554